ABC294640 is a selective and orally available Sphingosine kinase 2 inhibitor (SphK2 or SK2) in vitro, acting as a competitive inhibitor with respect to sphingosine with a Ki of 9.8 μM, and attenuates S1P formation in intact cells. In tissue culture, ABC294640 suppresses the proliferation of a broad panel of tumor cell lines, and inhibits tumor cell migration concomitant with loss of microfilaments. ABC294640 shows in vivo SK inhibitory activity in mice. Drug candidate for the treatment of cancer and other diseases.

KEYWORDS: ABC294640 | supplier | SphK2 inhibitor  | Opaganib | ABC 294640 | ABC-294640 | CAS [915385-81-8] | [1185157-59-8] | Sphingosine | SphK | Inhibitor | Enzymes | Ulcerative colitis | Crohn’s Disease | Inflammatory bowel disease